Drug major Sun Pharamaceutical Industries Ltd closed last fiscal with a net loss of Rs.1,073.36 crore on a standalone basis and is mulling a buy-back of its shares.
In a regulatory filing with BSE late Monday, the company said has posted a net loss of Rs 1,073.36 crore for the year ended March 31, 2016 as against a net loss of Rs.1,474.13 crore for the year ended March 31, 2015.
The company earned a total income of Rs.7,831.70 crore for the year ended March 31, 2016 against Rs.8,133.42 crore for the year ended March 31, 2015.
According to a company statement, the board of directors of Sun Pharmaceuticals has decided to meet on June 23 to evaluate a proposal for buy-back of equity shares.
On a consolidated basis the Sun Pharmaceuticals group has posted a net profit of Rs. 4,715.91 crore for the year ended March 31, 2016 against Rs.4,539.38 crore for the year ended March 31, 2015.
The group's total income stood at Rs.28,728.95 crore for the year ended March 31, 2016 against Rs.27,842.84 crore for the year ended March 31, 2015.
Meanwhile the Sun Pharamaceuticals share plunged by 5.70 percent to Rs.766.20 during the morning trade on Tuesday in BSE.
The Sun Pharmaceuticals scrip had closed at Rs.812.50 on Monday.
--IANS
vj/pgh/vm
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
